Novartis combo therapy for melanoma gets FDA priority review

Novartis combo therapy for melanoma gets FDA priority review



The U.S. Food and Drug Administration has granted priority review for Novartis's Tafinlar in combination with Mekinist for treating some patients with advanced melanoma.